Cidara Therapeutics Inc [CDTX] stock prices are up 0.04% to $220.89 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CDTX shares have gain 0.01% over the last week, with a monthly amount glided 0.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cidara Therapeutics Inc [NASDAQ: CDTX] stock has seen the most recent analyst activity on November 17, 2025, when RBC Capital Mkts downgraded its rating to a Sector Perform. Previously, Morgan Stanley downgraded its rating to Equal-Weight on November 17, 2025. On November 17, 2025, downgrade downgraded it’s rating to Neutral. Morgan Stanley started tracking the stock assigning an Overweight rating and suggested a price target of $190 on October 16, 2025. JP Morgan initiated its recommendation with an Overweight and recommended $200 as its price target on October 10, 2025. In a note dated March 12, 2025, Citizens JMP initiated an Mkt Outperform rating and provided a target price of $46 on this stock.
The stock price of Cidara Therapeutics Inc [CDTX] has been fluctuating between $15.22 and $221.20 over the past year. Currently, Wall Street analysts expect the stock to reach $177.88 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $220.89 at the most recent close of the market. An investor can expect a potential drop of -19.47% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.6 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 220.77 points at the first support level, and at 220.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 220.98, and for the 2nd resistance point, it is at 221.08.
Ratios To Look Out For
It’s worth pointing out that Cidara Therapeutics Inc [NASDAQ:CDTX]’s Current Ratio is 4.62. In addition, the Quick Ratio stands at 4.62 and the Cash Ratio stands at 3.06.
Transactions by insiders
Recent insider trading involved Ward Shane, COO & CLO, that happened on Dec 10 ’25 when 9959.0 shares were sold. Chief Medical Officer, Davarpanah Nicole Negar completed a deal on Sep 11 ’25 to sell 474.0 shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. bought 2.27 million shares on Jun 26 ’25.
